Psy Therapeutics
Boston, US · Delaware corporation
Founders & leadership
DS
David S. BarlowinExecutive
WW
William WagnerinExecutive
JT
Jeff TrodermanExecutive
BR
Bryan RobertsNamed on SEC filing
BB
Brant BinderNamed on SEC filing
Board
PM
Paul MurphyBoard director
AC
Alan CrossBoard director
JF
Jerry F. RosenbaumBoard director
DW
Daniel Weiss PickBoard director
Reported raises · per SEC filings
Form D private placements$10.7M disclosed across 2 of 3 rounds · 2019–2024
▶$6.8MraisedSep 2025 · 23 investors · PharmaceuticalsRule 506(b)
▶$6.8MraisedSep 2025 · 23 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David S. BarlowExecutive Officer, Director
- Paul MurphyDirector
- Alan CrossDirector
- William WagnerExecutive Officer
- Jerry F. RosenbaumDirector
- Daniel Weiss PickDirector
- Jeff TrodermanExecutive Officer
- Offering amount
- $20.4M
- Amount sold
- $6.8M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedOct 2019 · 19 investors · Other Health CareRule 506(b)
▶$4MraisedOct 2019 · 19 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Bryan RobertsDirector
- David S. BarlowExecutive Officer, Director
- Alan CrossExecutive Officer
- Daniel Weiss PickDirector
- Brant BinderExecutive Officer, Director
- Offering amount
- $4.3M
- Amount sold
- $4M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- How much funding has Psy Therapeutics raised?
- Psy Therapeutics has disclosed $10.7M raised across 2 of its 3 known rounds.
- Where is Psy Therapeutics headquartered?
- Psy Therapeutics is headquartered in Boston, US.